UnknownNCT05294835
Ketamine and Epigenetic Aging
Medication studyAges 18–64United StatesPTSD
Understand this study
Who could participate?
Listed age limits: 18 years to 64 years.
What will I do during this study?
The study group receives ketamine as a study medication.
- Listed locations
- LexingtonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 1, 2022
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 20
- Sponsor
- TruDiagnostic
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT05294835
- Official title
Show the full official title
Impact of Ketamine on Epigenetic Age (IKEA)
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Lexington
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is TruDiagnostic.
Does this study involve medication?
Yes. The study involves medication, including ketamine.
Who can participate?
Listed age limits: 18 years to 64 years.
